Depo-SubQ Provera 104 injection and Nerlynx
Determining the interaction of Depo-SubQ Provera 104 injection and Nerlynx and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with neratinib may reduce the efficacy of hormonal contraceptives. The mechanism for the potential interaction has not been established. There are no clinical data regarding the use of neratinib with hormonal contraceptives. MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with neratinib and for up to 1 month after discontinuing treatment. Women using hormonal contraceptives should add a barrier method. In addition, men receiving neratinib should use a barrier method of contraception during treatment and for 3 months after discontinuing treatment. References Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with neratinib may reduce the efficacy of hormonal contraceptives. The mechanism for the potential interaction has not been established. There are no clinical data regarding the use of neratinib with hormonal contraceptives.
MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with neratinib and for up to 1 month after discontinuing treatment. Women using hormonal contraceptives should add a barrier method. In addition, men receiving neratinib should use a barrier method of contraception during treatment and for 3 months after discontinuing treatment.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: medroxyprogesterone
Brand name: Depo-Provera, Depo-Provera Contraceptive, Depo-subQ provera 104, Provera
Synonyms: Depo-SubQ Provera 104 (injection), Depo-SubQ Provera 104
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Depo-SubQ Provera 104 injection-Neruo-K-500
- Depo-SubQ Provera 104 injection-Nesacaine
- Depo-SubQ Provera 104 injection-Nesacaine-MPF
- Depo-SubQ Provera 104 injection-Nesina
- Depo-SubQ Provera 104 injection-Nesiritide
- Depo-SubQ Provera 104 injection-Nesiritide Intravenous
- Nerlynx-Depo-Testosterone
- Nerlynx-DepoCyt
- Nerlynx-DepoDur
- Nerlynx-Deprizine
- Nerlynx-Deprizine FusePaq
- Nerlynx-Derma Gran AF Topical